IMMP

Immutep Ltd ADR

IMMP, USA

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

https://www.immutep.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IMMP
stock
IMMP

Will Marshall Machines Limited Hold Gains Into Close - Market Insider Reports & Small Investment Capital Gains Bollywood Helpline

Read more →
IMMP
stock
IMMP

Immutep (IMMP) scores win after announcing deal with Indian firm MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

STRONG BUY

Target Price:

$9.5

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

2.62

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-27.19 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-24.88 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-1,768.77 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.09

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 1.54% of the total shares of Immutep Ltd ADR

1.

BlackRock Inc

(0.4087%)

since

2025/06/30

2.

iShares Biotechnology ETF

(0.391%)

since

2025/08/31

3.

Meridian Wealth Management, LLC

(0.2539%)

since

2025/06/30

4.

Sender Co & Partners, Inc.

(0.0836%)

since

2025/06/30

5.

Morgan Stanley - Brokerage Accounts

(0.0814%)

since

2025/06/30

6.

UBS Group AG

(0.0442%)

since

2025/06/30

8.

Susquehanna International Group, LLP

(0.0397%)

since

2025/06/30

9.

Dimensional Fund Advisors, Inc.

(0.0308%)

since

2025/06/30

10.

Verition Fund Managegment, LLC

(0.03%)

since

2025/06/30

11.

LPL Financial Corp

(0.0232%)

since

2025/06/30

12.

Rhumbline Advisers

(0.0182%)

since

2025/06/30

13.

FNY Investment Advisers, LLC

(0.0129%)

since

2025/06/30

14.

Geode Capital Management, LLC

(0.0128%)

since

2025/06/30

15.

Fidelity Nasdaq Composite Index

(0.0128%)

since

2025/07/31

16.

XTX Topco Ltd

(0.0109%)

since

2025/06/30

17.

Bank of America Corp

(0.0061%)

since

2025/06/30

18.

Brighthouse/Dimensional Intl Sm Cm A

(0.0061%)

since

2025/06/30

19.

HighTower Advisors, LLC

(0.0055%)

since

2025/06/30

20.

DFA International Small Company I

(0.0044%)

since

2025/07/31

21.

DFA International Core Equity 2 I

(0.0038%)

since

2025/07/31

22.

DFA International Core Equity Class F

(0.0037%)

since

2025/06/30

23.

LVIP Dimensional Intl Core Eq Std

(0.0034%)

since

2025/06/30

24.

Tower Research Capital LLC

(0.0029%)

since

2025/06/30

25.

DFA Intl Sustainability Core 1

(0.0029%)

since

2025/07/31

26.

Dimensional Global Small Coms USD Acc

(0.0024%)

since

2025/06/30

27.

Royal Bank of Canada

(0.0014%)

since

2025/06/30

28.

DFA Asia Pacific Small Company I

(0.0006%)

since

2025/07/31

29.

GAMMA Investing LLC

(0.0004%)

since

2025/06/30

30.

SIMPLEX TRADING, LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1467

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.